MITRA — Mithra Pharmaceuticals SA Share Price
0.000.00%
Last trade - 00:00- €15.62m
- €212.50m
- €40.16m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.39 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -76.21% | ||
| Return on Equity | n/a | ||
| Operating Margin | -346.49% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 96.52 | 9.03 | 22.67 | 67 | 40.16 | 54.1 | 82.3 | -7.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mithra Pharmaceuticals SA is a Belgian-based company active in the pharmaceutical industry. The Company is a biotech company providing solutions in a field of women’s health, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. The Company provides three development candidates built on Mithra’s estrogen platform, Estetrol (E4): Estelle, a solution for oral contraception, PeriNesta, the oral treatment targeting perimenopause and Donesta, a hormone therapy. The Company also develops and manufactures therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. The Company operates in more than 100 countries around the world and is headquartered in Liege, Belgium.
Directors
- Patricia Van Dijck NEC
- Leon Van Rompay CEO
- Christophe Marechal CFO
- Jean-Michel Foidart CEX
- Graham Dixon CSO (59)
- Jean-Manuel Fontaine VPR
- Renaat Baes OTH
- Benjamin Brands OTH
- Frederic Constant OTH
- Cedric Darcis OTH
- Maud Vanderthommen OTH
- Francois Fornieri NED
- M. Christian Moretti NED (75)
- Gaetan Servais NED
- Koen Hoffman IND (53)
- Ajit Shetty IND (75)
- Erik Van den Eynden IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 13th, 1999
- Public Since
- June 30th, 2015
- No. of Employees
- 229
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Euronext - Brussels
- Shares in Issue
- 69,108,397
- Address
- Rue Saint-Georges 5, LIEGE, 4000
- Web
- https://www.mithra.com/
- Phone
- +32 43492822
- Auditors
- BDO Reviseurs d Entreprises
Upcoming Events for MITRA
Mithra Pharmaceuticals SA Annual Shareholders Meeting
Half Year 2024 Mithra Pharmaceuticals SA Earnings Release
Similar to MITRA
Biosenic SA
Euronext - Brussels
Fagron NV
Euronext - Brussels
Hyloris Pharmaceuticals SA
Euronext - Brussels
Financiere de Tubize SA
Euronext - Brussels
UCB SA
Euronext - Brussels
FAQ
What is the Mithra Pharmaceuticals SA share price?
As of Today at 19:14 UTC, shares in Mithra Pharmaceuticals SA are trading at €0.23. This share price information is delayed by 15 minutes.
How has the Mithra Pharmaceuticals SA share price performed this year?
Shares in Mithra Pharmaceuticals SA last closed at €0.23 and the price had moved by -92.87% over the past 365 days. In terms of relative price strength the Mithra Pharmaceuticals SA share price has underperformed the FTSE Global All Cap Index by -93.42% over the past year.
What are the analyst and broker recommendations for Mithra Pharmaceuticals SA?
The overall consensus recommendation for Mithra Pharmaceuticals SA is Sell. You can view the full broker recommendation list by unlocking its StockReport.
What is the Mithra Pharmaceuticals SA dividend yield?
Mithra Pharmaceuticals SA does not currently pay a dividend.
Does Mithra Pharmaceuticals SA pay a dividend?
Mithra Pharmaceuticals SA does not currently pay a dividend.
When does Mithra Pharmaceuticals SA next pay dividends?
Mithra Pharmaceuticals SA does not currently pay a dividend.
How do I buy Mithra Pharmaceuticals SA shares?
To buy shares in Mithra Pharmaceuticals SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mithra Pharmaceuticals SA?
As of the previous close price of €0.23, shares in Mithra Pharmaceuticals SA had a market capitalisation of €15.62m.
Where are Mithra Pharmaceuticals SA shares listed?
Here are the trading details for Mithra Pharmaceuticals SA:
- Country of listing: Belgium
- Exchange: BRU
- Ticker Symbol: MITRA
What kind of share is Mithra Pharmaceuticals SA?
Based on an overall assessment of its quality, value and momentum Mithra Pharmaceuticals SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mithra Pharmaceuticals SA share price forecast for 2024?
The analyst consensus target price for shares in Mithra Pharmaceuticals SA is €3.70. That is 1537.17% above the last closing price of €0.23.
Analysts covering Mithra Pharmaceuticals SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.57 for the next financial year.
What is the trend in the Mithra Pharmaceuticals SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mithra Pharmaceuticals SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -82.35%.
As of the last closing price of €0.23, shares in Mithra Pharmaceuticals SA were trading -82.64% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mithra Pharmaceuticals SA PE Ratio?
The Mithra Pharmaceuticals SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mithra Pharmaceuticals SA?
Mithra Pharmaceuticals SA's management team is headed by:
- Patricia Van Dijck - NEC
- Leon Van Rompay - CEO
- Christophe Marechal - CFO
- Jean-Michel Foidart - CEX
- Graham Dixon - CSO
- Jean-Manuel Fontaine - VPR
- Renaat Baes - OTH
- Benjamin Brands - OTH
- Frederic Constant - OTH
- Cedric Darcis - OTH
- Maud Vanderthommen - OTH
- Francois Fornieri - NED
- M. Christian Moretti - NED
- Gaetan Servais - NED
- Koen Hoffman - IND
- Ajit Shetty - IND
- Erik Van den Eynden - IND